Eddie Pharmaceuticals' improved new drug ADC119 tablets, a class 2.3 anti-HIV drug, has been approved for clinical trials.

Recently, Jiangsu Edi Pharmaceutical Group received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The company's independently developed 2.3-type improved new drug ADC119 tablets have been officially approved to conduct clinical trials, intended to be used as part of a comprehensive regimen for treating adult HIV-1 infection initial treatment patients.